...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of investigative dermatology. >Toward personalized medicine in scleroderma: Classification of scleroderma patients into stable 'inflammatory' and 'fibrotic' subgroups
【24h】

Toward personalized medicine in scleroderma: Classification of scleroderma patients into stable 'inflammatory' and 'fibrotic' subgroups

机译：向硬皮病寻求个性化药物：将硬皮病患者分为稳定的“炎症”和“纤维化”亚组

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is no universally agreed-upon treatment for the fibrosis of scleroderma. Recently, much information has been generated relating to the fundamental mechanisms underlying this disease. Partly based on these observations, both anti-inflammatory and anti-fibrotic agents have been considered as possible therapies. However, this information has not been successfully translated into clinical practice. In this issue, Pendergrass et al. use genome-wide expression profiling to provide valuable insights into scleroderma. Previously, the authors showed that morphea and limited scleroderma patients and a small subset of diffuse scleroderma (dSSc) patients express an inflammatory profile, whereas the majority of dSSc patients express a fibroproliferative profile. In the current study, the investigators show that the gene expression profile of these patients is fixed over time; i.e., in contrast to a previously held belief, the inflammatory patients do not go on to become fibrotic, and vice versa. These data suggest that expression profiling might be used to design clinical trials for scleroderma. The inflammatory patients might be treated with anti-inflammatory agents, whereas fibroproliferative patients might be treated with antifibrotic agents.
机译：目前尚无公认的硬皮病纤维化治疗方法。最近，已经产生了许多与该疾病潜在的基本机制有关的信息。部分基于这些观察，抗炎药和抗纤维化药均被认为是可能的治疗方法。但是，此信息尚未成功转换为临床实践。在本期中，Pendergrass等人。使用全基因组表达谱分析提供对硬皮病的宝贵见解。以前，作者表明吗啡和有限硬皮病患者以及一小部分弥漫性硬皮病（dSSc）患者表现出炎症特征，而大多数dSSc患者表现出纤维增生特征。在当前的研究中，研究人员表明，这些患者的基因表达谱随时间是固定的。即，与先前持有的信念相反，炎症患者不会继续纤维化，反之亦然。这些数据表明表达谱分析可用于设计硬皮病的临床试验。炎性患者可以用抗炎药治疗，而纤维增生患者可以用抗纤维化药治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号